Top two U.S. dialysis player, DaVita, has seen its fair share of headlines over the past year – an upcoming California ballot on dialysis reimbursement, charitable premium assistance controversy, and a pending sale of DMG. What does all this mean for DaVita’s ratings? Healthcare analysts, Ji Liu and Arthur Wong, discuss on the Beat what they are focusing on for the ratings on DaVita.